首页> 外文期刊>Retina >Clinical phenotype as a prognostic factor in Stargardt disease.
【24h】

Clinical phenotype as a prognostic factor in Stargardt disease.

机译:临床表型是Stargardt病的预后因素。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To determine the prognostic significance of widespread flecks, described as fundus flavimaculatus, in patients with Stargardt disease. DESIGN: Historical cohort study. SUBJECTS AND METHODS: Patients with Stargardt disease were identified by searching preexisting databases at the University of Iowa and Oregon Health Sciences University. The medical records of these patients were evaluated for the validity of the diagnosis, initial and final visual acuity, length of follow-up, and initial and final phenotype. Phenotype was graded as I, II, or III on the basis of the distribution of flecks and the extent of atrophy. The relationship between final visual acuity and final clinical appearance (phenotype I versus II versus III) was evaluated controlling for length of follow-up and age using a Cochran-Mantel-Haenszel test. The clinical progression of visual acuity loss for each phenotype was analyzed using life tables and Kaplan-Meier survival analysis for age and length of follow-up effects. RESULTS:A total of 214 patients were confirmed to have Stargardt disease; 131 patients were seen at multiple visits. Eighty-two patients were identified with phenotype I, 62 with phenotype II, and 70 with phenotype III. The final visual outcome was significantly better for patients whose ophthalmoscopic abnormalities were limited to the macula (phenotype I): 80 of 82 patients with phenotype I (97.6%) maintained 20/200 or better visual acuity in at least one eye as compared to 40/62 (64.5%) patients with phenotype II and 13/70 (18.6%) patients with phenotype III (P < 0.0001). Survival analysis showed a similarly significant difference in the survival probabilities (likelihood of maintaining 20/200 or better vision) for the three phenotypes considered over age and over follow-up length (P < 0.0001), with phenotypes II and III demonstrating significantly more deterioration in vision over time. CONCLUSIONS: The presence of midperipheral flecks, especially early in life, carries a poorer visual prognosis for patients withStargardt disease than when disease is limited to the macula. The development of midperipheral flecks is an indicator of more extensive fundus involvement and thus poorer long-term visual prognosis.
机译:目的:确定患有Stargardt病的患者中广泛存在的斑点(被称为眼底黄韧带)的预后意义。设计:历史队列研究。受试者和方法:通过搜索爱荷华大学和俄勒冈州健康科学大学的现有数据库,鉴定患有Stargardt病的患者。对这些患者的病历进行诊断有效性,初始和最终视力,随访时间以及初始和最终表型的评估。根据斑点的分布和萎缩的程度,将表型分为I,II或III级。使用Cochran-Mantel-Haenszel检验控制了随访时间和年龄,评估了最终视力与最终临床表现之间的关系(表型I与II与III)。使用生命表和Kaplan-Meier生存分析法分析了每种表型视力丧失的临床进展,以了解年龄和随访时间的长短。结果:总共214例患者被确认患有Stargardt病。多次就诊131例患者。鉴定出八十二名患者为I型,62名为II型,70名为III型。对于检眼镜异常仅限于黄斑的患者,最终的视觉效果明显更好(表型I):82例表型I患者中的80例(97.6%)在至少一只眼睛中保持20/200或更好的视力,相比之下,40例/ 62(64.5%)表型II患者和13/70(18.6%)表型III患者(P <0.0001)。生存分析表明,考虑到年龄和随访时间长短(P <0.0001)的三种表型的生存概率(维持20/200或更好的视力的可能性)具有相似的显着差异,表型II和III表现出明显更多的恶化随着时间的流逝。结论:Stargardt病患者的中周斑点的存在,特别是生命的早期,比仅限于黄斑病的患者的视觉预后较差。周围中央斑点的发展是更广泛的眼底受累的指标,因此长期视觉预后较差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号